On Oct. 30, 2020, Novavax announced the expansion of its Maryland campus to accommodate the companyﾒs rapid growth as it works to develop its candidate vaccine against COVID-19 and advance its influenza vaccine for global markets.

Novavax secured two additional properties in Gaithersburg, Maryland to support the Companyﾒs immediate need for additional laboratory and office space for manufacturing, R&D and business operations.